01—Abstract
Summary
Summary of the 10-K filed March 13, 2009. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (filed under this name; now trading on NASDAQ as HALO) reported its annual results for fiscal 2008 in this Form 10-K, filed March 13, 2009.
The company is a biopharmaceutical company focused on products targeting the extracellular matrix, built on its recombinant human PH20 hyaluronidase enzyme (rHuPH20). Total revenues were $8,764,139a in 2008, up from $3,799,521 in 2007, but net loss widened to $48,654,199 ($0.61 per share) from $23,896,183 ($0.32 per share), driven by research and development expense rising to $44,232,936 from $20,554,105. The company has never been profitable, with an accumulated deficit of $113.6 million as of December 31, 2008.
At year-end 2008, cash and cash equivalents were $63,715,906,b down from $97,679,085, and stockholders' equity fell to $15,379,996 from $57,767,924. Management believes current cash will fund operations for at least the next twelve months and expects net cash burn of approximately $30.0 to $35.0 million for 2009. The company's revenue depends heavily on partners: Baxter accounted for 51% and Roche for 44% of 2008 total revenues.
Management stated that Baxter's sales and marketing resources for HYLENEX have not met its expectations, and the company decided in early 2009 to reallocate resources away from its Chemophase bladder cancer program. Key pipeline items include a Phase II trial of rHuPH20 combined with insulin in Type 1 diabetic patients (started November 2008), a first Phase I trial of PEGPH20 in advanced solid tumors, and a Phase III trial of GAMMAGARD LIQUID with rHuPH20 announced for January 2009. The company also disclosed a universal shelf registration of up to $50.0 millionc and approximately 1.9 million warrants outstanding that expire in October 2009.
02—Key points
Key Highlights
- Total revenues rose to $8,764,139 in 2008 from $3,799,521 in 2007, with collaboration revenues of $8,052,202 and product sales of $711,937.
- Net loss increased to $48,654,199, or $0.61 per share, compared with a net loss of $23,896,183, or $0.32 per share, in 2007.
- Research and development expenses were $44,232,936 in 2008, up from $20,554,105 in 2007, mainly due to outsourced development costs and manufacturing scale-up of rHuPH20.
- Cash and cash equivalents declined to $63,715,906 at December 31, 2008 from $97,679,085; net cash used in operations was $35,373,864.
- Stockholders' equity decreased to $15,379,996 from $57,767,924, and the accumulated deficit reached $113,649,622.
- Management expects net cash burn of approximately $30.0 to $35.0 million in 2009 and believes current cash is sufficient for at least the next twelve months.
- Baxter (51%) and Roche (44%) together accounted for substantially all of 2008 total revenues, and management said Baxter's HYLENEX sales efforts have not met its expectations.
03—Questions
Frequently Asked Questions
Is the company generating meaningful revenue from its own products?
Not yet. Product sales were $711,937 in 2008, from HYLENEX (sold through Baxter) and Cumulase. Most revenue came from collaboration agreements with Baxter and Roche, including amortization of upfront fees and reimbursements of research and development services. The filing states that revenues are not expected to fund operations for at least several years.
How much cash does the company have and how long will it last?
Cash and cash equivalents were $63.7 million at December 31, 2008. Management believes this is sufficient to fund operations for at least the next twelve months and anticipates a 2009 net cash burn of approximately $30.0 to $35.0 million. The company states it may need to raise additional capital, through public offerings, new or revised collaborations, private financings or other equity or debt financings.
What are the main risks tied to the company's partners?
The filing says Baxter's resource allocation has resulted in disappointing HYLENEX sales and that there is no assurance Baxter will increase those resources. Both Baxter and Roche account for large shares of revenue, and the termination or non-performance of a key collaboration agreement could significantly affect the business.
What are the key clinical programs and their timing?
The Insulin-PH20 Phase II study began in November 2008, with results expected for presentation in mid-2009. The PEGPH20 program started a first Phase I trial in patients with advanced solid tumors. A Phase III trial of GAMMAGARD LIQUID with rHuPH20 was announced in January 2009. The Chemophase program is being deprioritized, and the company is exploring strategic alternatives for it.
Could shareholders face dilution in the near term?
Possibly. Warrants for about 1.9 million shares remain outstanding at $2.25 per share and expire in October 2009. The company also has a universal shelf registration allowing up to $50.0 million of equity or debt securities, and it may use it to raise capital in the next twelve months.
04—Continue